Thomas Axelsson

Thomas Axelsson discloses dealings in 2 companies, chiefly Vitrolife AB and Vitrolife Sweden AB. Over a trading history stretching from 8 August 2016 to 28 October 2022, the count stands at 6 filings.

Market trades split into 3 purchases (€209k) and 3 sales (€2.7M). Netting one side against the other leaves €2.5M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. In 2022 alone, the filings show 1 purchase and no sales.

In size, the median ticket on the buying side is €11k. Of 3 purchases, 2 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster.

The newest entry dates from 28 October 2022: an open-market purchase of €194k, in Vitrolife Sweden AB. Half of the filings or more reach the Finansinspektionen feed on the day of the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades. These figures are compiled from regulatory filings published by Finansinspektionen. They describe what insiders did and are not a recommendation.